Life Science Tech Trends SupplementBack to Survey IndexIs your equipment "state-of-the-art"?
What capital improvements are needed?
How much will you spend?
What tools and technologies will you use?
Age and Technological Capabilities of Research-related Capital Equipment
Four out of 10 researchers reported that their capital equipment was "state-of-the-art." However, the majority say their tools are dated, or lack needed capabilities.
Changes That Will Require Capital Investments
Almost nine of ten of the organizations (85%) will have experienced changes in 2007-2008 that require capital investments.
Expected Change in Research-related Capital Expenditures, 2007 to 2008
From 2007 to 2008, most respondents project budgets to be either the same (65%) or higher (30%) in terms of research-related capital expenditures.
Organization’s Adoption of Emerging Technologies
Respondents were asked to indicate the cutting edge/emerging technologies their organizations will use over the next 24 to 36 months. The technologies that have the greatest chances of being used are microscopy, spectrophotometry, mass spectrometry, HPLC, PCR, cell culture, and ELISAs/immunoassays.
|
% Respondents
|
|
Currently Use
|
Will Likely Use
|
Will
Possibly Use
|
Will
Outsource
|
No
Involvement
|
Microscopy
|
73.7 |
6.6 |
5.8 |
1.5 |
12.4 |
Spectrophotometry
|
69.2 |
9.5 |
3.7 |
2.2 |
15.4 |
Mass spectrometry
|
55.6 |
9.4 |
6.9 |
11.2 |
17.0 |
HPLC
|
59.2 |
7.4 |
7.7 |
6.6 |
19.1 |
PCR
|
63.2 |
3.3 |
6.7 |
4.8 |
21.9 |
Cell culture
|
61.2 |
6.5 |
4.7 |
5.4 |
22.1 |
ELISAs/Immunoassays
|
56.6 |
8.5 |
9.2 |
2.6 |
23.2 |
Protein analysis and expression
|
60.6 |
5.6 |
3.7 |
3.7 |
26.4 |
| Western blotting |
59.0
|
3.7
|
5.2
|
1.8
|
30.3
|
| Microarrays |
40.5
|
10.8
|
8.2
|
7.8
|
32.7
|
| Nucleic acid analysis |
48.5
|
6.4
|
6.4
|
5.6
|
33.1
|
| Bioinformatics |
41.8
|
6.6
|
14.3
|
4.0
|
33.3
|
| Flow cytometry |
46.7
|
6.7
|
7.8
|
4.4
|
34.4
|
| Sequencing |
39.8
|
5.3
|
6.0
|
13.9
|
35.0
|
| NMR, enhance |
32.6
|
7.9
|
9.7
|
9.7
|
40.1
|
| Compound library screening |
29.7
|
10.4
|
15.2
|
4.5
|
40.1
|
| Cloning |
39.6
|
8.9
|
6.3
|
3.7
|
41.5
|
| Proteomics |
29.9
|
11.5
|
9.2
|
6.1
|
43.3
|
| Robotics |
31.6
|
10.0
|
10.8
|
1.5
|
46.1
|
Ultra performance liquid
chromatography (UPLC) |
17.7
|
16.2
|
14.7
|
4.1
|
47.4
|
| RNA interference |
29.1
|
9.4
|
10.9
|
1.9
|
48.7
|
| Transgenic animals |
29.3
|
5.3
|
9.1
|
5.7
|
50.6
|
| Antibody production |
25.6
|
9.2
|
5.5
|
8.8
|
50.9
|
| High-content screening |
20.2
|
12.4
|
11.2
|
5.2
|
50.9
|
| Systems biology |
20.4
|
14.0
|
10.9
|
1.1
|
53.6
|
| Protein crystallization |
16.3
|
11.0
|
7.2
|
9.5
|
56.1
|
| SNP research |
23.8
|
7.7
|
9.2
|
1.5
|
57.7
|
| Metabolomics |
13.1
|
12.7
|
11.2
|
4.9
|
58.2
|
| SEM, enhanced |
18.1
|
7.9
|
6.0
|
8.3
|
59.6
|
| Stem cells |
17.7
|
8.1
|
9.6
|
2.3
|
62.3
|
| RFID (radio frequency ID tags) |
7.1
|
7.9
|
13.5
|
3.0
|
68.4
|
| Atomic force microscopy |
8.6
|
6.0
|
5.2
|
6.3
|
73.9
|
About This Survey
This survey was prepared and conducted by Martin Akel & Associates, Chester, N.J. for the Advantage Business Media Science Group’s publications, Bioscience Technology and Drug Discovery & Development magazines. The survey was sent to a random sample of readers in November, 2007.
